New hope for tough lung cancer: tarlatamab trial targets patients with poor health
NCT ID NCT07203053
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 33 times
Summary
This study tests a drug called tarlatamab in 48 people with advanced small cell lung cancer who have already tried one standard treatment. Participants receive tarlatamab through an IV until their cancer worsens or side effects become too severe. The main goal is to see how many patients are alive after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AO San Giovanni Addolorata
NOT_YET_RECRUITINGRoma, Italy
Contact
-
CHU Angers
NOT_YET_RECRUITINGAngers, France
Contact
-
Geneva University Hospitals
RECRUITINGGeneva, Switzerland
Contact
-
HFR - Hôpital cantonal
NOT_YET_RECRUITINGFribourg, Switzerland
Contact
-
Henry Dunant Hospital Center
NOT_YET_RECRUITINGAthens, Greece
Contact
-
Hospital General Universitario Alicante
NOT_YET_RECRUITINGAlicante, Spain
Contact
-
Hospital Universitatrio Puerta del Hierro
NOT_YET_RECRUITINGMadrid, Spain
Contact
-
Hospital Universitatrio Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, Spain
Contact
-
Hospital de la Santa Creu I Sant Pau
NOT_YET_RECRUITINGBarcelona, Spain
Contact
-
Hôpital Nord de Marseille
NOT_YET_RECRUITINGMarseille, France
Contact
-
ICO Hospitalet H. Duran I Reynals / H. Bellvitge
NOT_YET_RECRUITINGBarcelona, Spain
Contact
-
Institut Bergonie
NOT_YET_RECRUITINGBordeaux, France
Contact
-
Instituto Europeo di Oncologia (IEO)
NOT_YET_RECRUITINGMilan, Italy
Contact
-
Irccs Irst
NOT_YET_RECRUITINGMeldola, Italy
Contact
-
Istituto Nazionale Tumori "Regina Elena"
NOT_YET_RECRUITINGRoma, Italy
Contact
-
Kantonsspital Baden
RECRUITINGBaden, Switzerland
Contact
-
Kantonsspital St.Gallen
NOT_YET_RECRUITINGSankt Gallen, Switzerland
Contact
-
Lyon - Centre Léon Bérard
NOT_YET_RECRUITINGLyon, France
Contact
-
Santa Maria della Misericordia Hospital
NOT_YET_RECRUITINGPerugia, Italy
Contact
Conditions
Explore the condition pages connected to this study.